mianserin has been researched along with Cerebrovascular Disorders in 4 studies
Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.
Cerebrovascular Disorders: A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.
| Excerpt | Relevance | Reference |
|---|---|---|
| "(1) To test whether early prophylactic antidepressive treatment by mianserin is able to prevent poststroke depression, and (2) to discover whether mianserin as an antidepressant has any beneficial influence on the outcome of ischaemic stroke." | 9.09 | Prevention of poststroke depression: 1 year randomised placebo controlled double blind trial of mianserin with 6 month follow up after therapy. ( Berg, A; Hares, J; Kaste, M; Lehtihalmes, M; Lönnqvist, J; Lönnqvist, R; Palomäki, H, 1999) |
| "(1) To test whether early prophylactic antidepressive treatment by mianserin is able to prevent poststroke depression, and (2) to discover whether mianserin as an antidepressant has any beneficial influence on the outcome of ischaemic stroke." | 5.09 | Prevention of poststroke depression: 1 year randomised placebo controlled double blind trial of mianserin with 6 month follow up after therapy. ( Berg, A; Hares, J; Kaste, M; Lehtihalmes, M; Lönnqvist, J; Lönnqvist, R; Palomäki, H, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lauritzen, L | 1 |
| Bendsen, BB | 1 |
| Vilmar, T | 1 |
| Bendsen, EB | 1 |
| Lunde, M | 1 |
| Bech, P | 1 |
| De León, OA | 1 |
| Furmaga, KM | 1 |
| Kaltsounis, J | 1 |
| Palomäki, H | 1 |
| Kaste, M | 1 |
| Berg, A | 1 |
| Lönnqvist, R | 1 |
| Lönnqvist, J | 1 |
| Lehtihalmes, M | 1 |
| Hares, J | 1 |
| Hachinski, V | 1 |
2 trials available for mianserin and Cerebrovascular Disorders
| Article | Year |
|---|---|
Post-stroke depression: combined treatment with imipramine or desipramine and mianserin. A controlled clinical study.
Topics: Aged; Cerebrovascular Disorders; Depressive Disorder; Desipramine; Double-Blind Method; Drug Therapy | 1994 |
Prevention of poststroke depression: 1 year randomised placebo controlled double blind trial of mianserin with 6 month follow up after therapy.
Topics: Adult; Antidepressive Agents, Second-Generation; Cerebrovascular Disorders; Depression; Depressive D | 1999 |
2 other studies available for mianserin and Cerebrovascular Disorders
| Article | Year |
|---|---|
Mirtazapine-induced mania in a case of poststroke depression.
Topics: Aged; Antidepressive Agents, Tricyclic; Bipolar Disorder; Cerebrovascular Disorders; Depression; Hum | 1999 |
Post-stroke depression, not to be underestimated.
Topics: Aged; Antidepressive Agents, Second-Generation; Cerebrovascular Disorders; Depressive Disorder; Fema | 1999 |